326 related articles for article (PubMed ID: 33489819)
1. Decade in review: a new era for RET-rearranged lung cancers.
Choudhury NJ; Drilon A
Transl Lung Cancer Res; 2020 Dec; 9(6):2571-2580. PubMed ID: 33489819
[TBL] [Abstract][Full Text] [Related]
2. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
3. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
[TBL] [Abstract][Full Text] [Related]
4. Selective RET Inhibitors (SRIs) in Cancer: A Journey from Multi-Kinase Inhibitors to the Next Generation of SRIs.
Clark L; Fisher G; Brook S; Patel S; Arkenau HT
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201460
[TBL] [Abstract][Full Text] [Related]
5. Precision therapy for RET-altered cancers with RET inhibitors.
Thein KZ; Velcheti V; Mooers BHM; Wu J; Subbiah V
Trends Cancer; 2021 Dec; 7(12):1074-1088. PubMed ID: 34391699
[TBL] [Abstract][Full Text] [Related]
6. RET kinase alterations in targeted cancer therapy.
Liu X; Hu X; Shen T; Li Q; Mooers BHM; Wu J
Cancer Drug Resist; 2020; 3(3):472-481. PubMed ID: 35582449
[TBL] [Abstract][Full Text] [Related]
7.
Desilets A; Repetto M; Yang SR; Sherman EJ; Drilon A
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627175
[No Abstract] [Full Text] [Related]
8. Case report: identification of
Ma J; Wang B; Meng E; Meng X
Gland Surg; 2021 Sep; 10(9):2874-2879. PubMed ID: 34733735
[TBL] [Abstract][Full Text] [Related]
9. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue.
Takamori S; Matsubara T; Haratake N; Toyokawa G; Fujishita T; Toyozawa R; Ito K; Yamaguchi M; Taguchi K; Okamoto T; Seto T
Front Oncol; 2021; 11():704084. PubMed ID: 34497761
[TBL] [Abstract][Full Text] [Related]
11. Targeting RET-rearranged non-small-cell lung cancer: future prospects.
Bronte G; Ulivi P; Verlicchi A; Cravero P; Delmonte A; Crinò L
Lung Cancer (Auckl); 2019; 10():27-36. PubMed ID: 30962732
[TBL] [Abstract][Full Text] [Related]
12. Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.
Zheng H; Chen ZS; Li J
Drugs Today (Barc); 2021 Oct; 57(10):621-629. PubMed ID: 34713870
[TBL] [Abstract][Full Text] [Related]
13. Precision oncology with selective RET inhibitor selpercatinib in
Gouda MA; Subbiah V
Ther Adv Med Oncol; 2023; 15():17588359231177015. PubMed ID: 37360768
[TBL] [Abstract][Full Text] [Related]
14. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
Acharya B; Frett B
Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171
[TBL] [Abstract][Full Text] [Related]
15.
Osta BE; Ramalingam SS
JTO Clin Res Rep; 2020 Sep; 1(3):100050. PubMed ID: 34589946
[TBL] [Abstract][Full Text] [Related]
16. Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer.
O'Leary C; Xu W; Pavlakis N; Richard D; O'Byrne K
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31058838
[TBL] [Abstract][Full Text] [Related]
17. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
18. Beyond
Farago AF; Azzoli CG
Transl Lung Cancer Res; 2017 Oct; 6(5):550-559. PubMed ID: 29114471
[TBL] [Abstract][Full Text] [Related]
19. Predictive molecular pathology in metastatic thyroid cancer: the role of
Nacchio M; Pisapia P; Pepe F; Russo G; Vigliar E; Porcelli T; Luongo C; Iaccarino A; Pagni F; Salvatore D; Troncone G; Malapelle U; Bellevicine C
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):167-178. PubMed ID: 35404189
[TBL] [Abstract][Full Text] [Related]
20. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]